-
Something wrong with this record ?
Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells
M. Kuchař, L. Vaňková, H. Petroková, J. Cerný, R. Osička, O. Pelák, H. Sípová, B. Schneider, J. Homola, P. Sebo, T. Kalina, P. Malý,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24549990
DOI
10.1002/prot.24472
Knihovny.cz E-resources
- MeSH
- Anti-Inflammatory Agents chemistry pharmacology MeSH
- Bacterial Proteins chemistry MeSH
- K562 Cells MeSH
- Th17 Cells drug effects metabolism MeSH
- Immunologic Factors chemistry pharmacology MeSH
- Interleukin-23 chemistry physiology MeSH
- Jurkat Cells MeSH
- Binding, Competitive MeSH
- Humans MeSH
- Molecular Sequence Data MeSH
- Peptide Fragments chemistry pharmacology MeSH
- Drug Evaluation, Preclinical MeSH
- Receptors, Interleukin antagonists & inhibitors physiology MeSH
- Amino Acid Sequence MeSH
- Sequence Homology, Amino Acid MeSH
- Protein Binding MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Engineered combinatorial libraries derived from small protein scaffolds represent a powerful tool for generating novel binders with high affinity, required specificity and designed inhibitory function. This work was aimed to generate a collection of recombinant binders of human interleukin-23 receptor (IL-23R), which is a key element of proinflammatory IL-23-mediated signaling. A library of variants derived from the three-helix bundle scaffold of the albumin-binding domain (ABD) of streptococcal protein G and ribosome display were used to select for high-affinity binders of recombinant extracellular IL-23R. A collection of 34 IL-23R-binding proteins (called REX binders), corresponding to 18 different sequence variants, was used to identify a group of ligands that inhibited binding of the recombinant p19 subunit of IL-23, or the biologically active human IL-23 cytokine, to the recombinant IL-23R or soluble IL-23R-IgG chimera. The strongest competitors for IL-23R binding in ELISA were confirmed to recognize human IL-23R-IgG in surface plasmon resonance experiments, estimating the binding affinity in the sub- to nanomolar range. We further demonstrated that several REX variants bind to human leukemic cell lines K-562, THP-1 and Jurkat, and this binding correlated with IL-23R cell-surface expression. The REX125, REX009 and REX128 variants competed with the p19 protein for binding to THP-1 cells. Moreover, the presence of REX125, REX009 and REX115 variants significantly inhibited the IL-23-driven expansion of IL-17-producing primary human CD4(+) T-cells. Thus, we conclude that unique IL-23R antagonists derived from the ABD scaffold were generated that might be useful in designing novel anti-inflammatory biologicals.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014507
- 003
- CZ-PrNML
- 005
- 20150429092010.0
- 007
- ta
- 008
- 150420s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/prot.24472 $2 doi
- 035 __
- $a (PubMed)24549990
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kuchař, Milan $u Laboratory of Ligand Engineering, Institute of Biotechnology AS CR, v. v. i., Vídeňská 1083, 142 20 Prague, Czech Republic.
- 245 10
- $a Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells / $c M. Kuchař, L. Vaňková, H. Petroková, J. Cerný, R. Osička, O. Pelák, H. Sípová, B. Schneider, J. Homola, P. Sebo, T. Kalina, P. Malý,
- 520 9_
- $a Engineered combinatorial libraries derived from small protein scaffolds represent a powerful tool for generating novel binders with high affinity, required specificity and designed inhibitory function. This work was aimed to generate a collection of recombinant binders of human interleukin-23 receptor (IL-23R), which is a key element of proinflammatory IL-23-mediated signaling. A library of variants derived from the three-helix bundle scaffold of the albumin-binding domain (ABD) of streptococcal protein G and ribosome display were used to select for high-affinity binders of recombinant extracellular IL-23R. A collection of 34 IL-23R-binding proteins (called REX binders), corresponding to 18 different sequence variants, was used to identify a group of ligands that inhibited binding of the recombinant p19 subunit of IL-23, or the biologically active human IL-23 cytokine, to the recombinant IL-23R or soluble IL-23R-IgG chimera. The strongest competitors for IL-23R binding in ELISA were confirmed to recognize human IL-23R-IgG in surface plasmon resonance experiments, estimating the binding affinity in the sub- to nanomolar range. We further demonstrated that several REX variants bind to human leukemic cell lines K-562, THP-1 and Jurkat, and this binding correlated with IL-23R cell-surface expression. The REX125, REX009 and REX128 variants competed with the p19 protein for binding to THP-1 cells. Moreover, the presence of REX125, REX009 and REX115 variants significantly inhibited the IL-23-driven expansion of IL-17-producing primary human CD4(+) T-cells. Thus, we conclude that unique IL-23R antagonists derived from the ABD scaffold were generated that might be useful in designing novel anti-inflammatory biologicals.
- 650 _2
- $a sekvence aminokyselin $7 D000595
- 650 _2
- $a antiflogistika $x chemie $x farmakologie $7 D000893
- 650 _2
- $a bakteriální proteiny $x chemie $7 D001426
- 650 _2
- $a kompetitivní vazba $7 D001667
- 650 _2
- $a preklinické hodnocení léčiv $7 D004353
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunologické faktory $x chemie $x farmakologie $7 D007155
- 650 _2
- $a interleukin-23 $x chemie $x fyziologie $7 D053759
- 650 _2
- $a Jurkat buňky $7 D019169
- 650 _2
- $a buňky K562 $7 D020014
- 650 _2
- $a molekulární sekvence - údaje $7 D008969
- 650 _2
- $a peptidové fragmenty $x chemie $x farmakologie $7 D010446
- 650 _2
- $a vazba proteinů $7 D011485
- 650 _2
- $a receptory interleukinů $x antagonisté a inhibitory $x fyziologie $7 D018123
- 650 _2
- $a sekvenční homologie aminokyselin $7 D017386
- 650 _2
- $a buňky Th17 $x účinky léků $x metabolismus $7 D058504
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vaňková, Lucie
- 700 1_
- $a Petroková, Hana
- 700 1_
- $a Cerný, Jiří
- 700 1_
- $a Osička, Radim
- 700 1_
- $a Pelák, Ondřej
- 700 1_
- $a Sípová, Hana
- 700 1_
- $a Schneider, Bohdan
- 700 1_
- $a Homola, Jiří
- 700 1_
- $a Sebo, Peter
- 700 1_
- $a Kalina, Tomáš
- 700 1_
- $a Malý, Petr
- 773 0_
- $w MED00003938 $t Proteins $x 1097-0134 $g Roč. 82, č. 6 (2014), s. 975-89
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24549990 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150429092314 $b ABA008
- 999 __
- $a ok $b bmc $g 1072088 $s 897385
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 82 $c 6 $d 975-89 $i 1097-0134 $m Proteins $n Proteins $x MED00003938
- LZP __
- $a Pubmed-20150420